監管
EMA validates Pfizer and Valneva's Lyme disease vaccine application
The European Medicines Agency validated the Marketing Authorization Application for PF-07307405, the Lyme disease vaccine candidate developed by Pfizer with partner Valneva, and will begin its assessment. The application is based on Phase 3 VALOR trial efficacy of more than 70%, with no safety concerns identified.
文章預覽
Accessibility: Skip TopNav English French Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency August 14, 2026 01:00 ET | Source: VALNEVA SE VALNEVA SE Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies’ 6-valent outer surface pr…